《心房颤动患者二级预防中使用新型口服抗凝药》勘误
Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation.
出版信息
Eur Heart J Suppl. 2020 Oct 17;22(Suppl I):I12. doi: 10.1093/eurheartj/suaa122. eCollection 2020 Sep.
Abstract
[This corrects the article DOI: 10.1093/eurheartj/suaa104.][This corrects the article DOI: 10.1093/eurheartj/suaa104.].
摘要
[本文更正文章DOI：10.1093/eurheartj/suaa104。][本文更正文章DOI：10.1093/eurheartj/suaa104。]
相似文献
1
Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation.《心房颤动患者二级预防中使用新型口服抗凝药》勘误
Eur Heart J Suppl. 2020 Oct 17;22(Suppl I):I12. doi: 10.1093/eurheartj/suaa122. eCollection 2020 Sep.
2
The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.非维生素 K 拮抗剂口服抗凝剂（NOACs）在预防房颤患者中风中的作用。
Curr Neurol Neurosci Rep. 2016 May;16(5):47. doi: 10.1007/s11910-016-0645-6.
3
Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies.左心耳封堵术与新型口服抗凝药预防心房颤动卒中的1年以上疗效和安全性：随机对照试验和观察性研究的系统评价与荟萃分析
Heart Rhythm. 2016 Jun;13(6):1203-14. doi: 10.1016/j.hrthm.2015.12.037. Epub 2015 Dec 24.
4
Erratum to: Practice-derived data on Non-vitamin K antagonist Oral Anticoagulant (NOAC) therapy to complement observations from randomized trials.勘误：基于实践的数据用于非维生素K拮抗剂口服抗凝剂（NOAC）治疗，以补充随机试验的观察结果。
Eur Heart J Suppl. 2020 Oct 17;22(Suppl I):I21. doi: 10.1093/eurheartj/suaa121. eCollection 2020 Sep.
5
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.伴有单一卒中危险因素的房颤患者中标准剂量非维生素 K 拮抗剂口服抗凝剂和华法林的有效性和安全性：一项全国性队列研究。
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
6
Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis.口服抗栓药物用于心房颤动卒中预防的临床及安全性结局：一项系统评价与网状Meta分析
J Am Med Dir Assoc. 2015 Dec;16(12):1103.e1-19. doi: 10.1016/j.jamda.2015.09.008. Epub 2015 Oct 31.
7
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.评估新型口服抗凝剂在心房颤动卒中预防试验中疗效和安全性的网状Meta分析的批判性评价
Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28.
8
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.阿哌沙班与其他新型口服抗凝药预防心房颤动卒中的成本效益比较。
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.
9
Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.新型口服抗凝剂在伴有房颤的肥厚型心肌病患者中的一级卒中预防作用。
Stroke. 2019 Sep;50(9):2582-2586. doi: 10.1161/STROKEAHA.119.026048. Epub 2019 Jul 25.
10
Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.非维生素 K 口服抗凝剂（NOACs）预防二次中风。
Expert Opin Pharmacother. 2018 Oct;19(14):1597-1602. doi: 10.1080/14656566.2018.1515913. Epub 2018 Sep 17.
Zotero 插件